Bluebird bio, Inc.
BLUE
Rang in aandelen
#15671
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Aandeelprijs
$4.97
Laatst gesynchroniseerd: 2025-06-02
Marktkapitalisatie
$318.62M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-38.03%
Land
US
Handel Bluebird bio, Inc. (BLUE)
Categorie
Healthcare
Marktkapitalisatie van Bluebird bio, Inc.(BLUE)
Marktkapitalisatie: $318.62M
Vanaf October 2026 heeft Bluebird bio, Inc. een marktkapitalisatie van $318.62M. Dit maakt Bluebird bio, Inc. volgens onze gegevens het 15671st meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Bluebird bio, Inc. van 2018 tot 2026
BLUE vergeleken met de top 5 populairste stocks
